The recent study by Srivastava et al. [9] offers a compelling preclinical framework for overcoming this resistance by targeting nitric oxide (NO)-mediated S-nitrosylation, a reversible post-translational modification (PTM) that appears to regulate both signaling and immune evasion in NRAS-driven melanomas. The gene discussed is NRAS; the disease is melanoma.